Matinas BioPharma Holdings Inc MTNB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $0.34
- Day Range
- $0.32–0.38
- 52-Week Range
- $0.31–3.09
- Bid/Ask
- $0.34 / $0.34
- Shares Outstanding
- 13.69M
- Market Cap
- $2.17M
- Volume/Avg
- 1M / 477,218
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 2
- Website
- https://www.matinasbiopharma.com
Valuation
|
Metric
|
MTNB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.72 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MTNB
|
|---|---|
Quick Ratio | 1.13 |
Current Ratio | 1.32 |
Interest Coverage | — |
Quick Ratio
MTNB
Profitability
|
Metric
|
MTNB
|
|---|---|
Return on Assets (Normalized) | −68.90% |
Return on Equity (Normalized) | −112.73% |
Return on Invested Capital (Normalized) | −83.00% |
Return on Assets
MTNB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|yG@BZq | LOCK|@vzG> | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|gJ&m&b? | LOCK|%s#< | $70B | |||
| argenx SE ADR
ARGX
| LOCK|t^t<#% | LOCK|jX | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!>x#@y | LOCK|<>$r | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|D&$C>v% | LOCK|hh | $37B | |||
| Moderna Inc
MRNA
| LOCK|#NxZs&$ | LOCK|>J | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>R<Fzf@ | LOCK|GddWn | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|>PD@Fcl | LOCK|qj | $23B | |||
| Incyte Corp
INCY
| LOCK|HW>%!tz | LOCK|^# | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|#p$KTG^ | LOCK|%Qh | $16B |
United States